

Highly Potent HIV-1 Protease Inhibitors with Polycyclic-THF Ligands

Track Code: 2020-GHOS-68891

Categories:

- Chemistry and Chemical Analysis
- Pharmaceuticals

Keywords:

- Chemistry and Chemical Analysis
- Drug Development
- HIV/AIDS
- Medicinal Chemistry
- Pharmaceutical Analysis
- Pharmaceutical Research
- Pharmaceuticals
- Pharmacology

NCS: Researchers at Purdue University have designed and developed a new class of highly potent HIV-1 protease inhibitors with polycyclic-THF ligands for treatment of human immunodeficiency virus type 1 (HIV-1). Improvement of current HIV protease inhibitors is needed to combat drug-resistant HIV strains. Although antiretroviral therapies (ART) have had a major impact on the AIDS epidemic, they have not eradicated HIV-1 in part due to the viral reservoirs remaining in blood and infected tissues. Purdue researchers developed novel protease inhibitors with improved properties over darunavir. In testing in vitro, the new inhibitors showed 100-fold increased antiviral activity against drug resistant strains of HIV-1 relative to darunavir. The high yielding synthetic schemes (79-90%) of these inhibitors and derivatives offer an encouraging potential for reaction scale-up. Moreover, structurally, these compounds are expected to have good pharmacokinetic properties for drug development.

Technology Validation: High resolution crystal structures of inhibitor bound wild-type HIV-1 protease have shown increased binding properties compared to darunavir. The new protease inhibitors have also been tested in vitro wherein they exhibit improved treatment of HIV-1 over darunavir by 100-fold.

Advantages:

- High antiviral activity against resistant HIV-1
- Structurally promising pharmacokinetic properties
- High yield synthesis

Applications:

- HIV-1 therapeutics
- Drug discovery

Related Publications:

"Design and Development of Highly Potent HIV-1 Protease Inhibitors with a Crown-Like Oxotricyclic Core as the P2-Ligand to Combat Multidrug-Resistant HIV Variants"

Journal of Medicinal Chemistry

DOI: 10.1021/acs.jmed.chem.7b00172

"Design of Highly Potent, Dual Acting and Central Nervous System Penetrating HIV-1 Protease Inhibitors with Excellent Potency against Multidrug-Resistant HIV-1 Variants"

ChemMedChem

DOI: 10.1002/cmdc.201700824

People:

- Ghosh, Arun K (Project leader)
- Kovela, Satish
- Mitsuya, Hiroaki

Intellectual Property:

Application Date: September 16, 2022

Type: NATL-Patent

Country of Filing: United States

Patent Number: (None)

Issue Date: (None)

Application Date: January 18, 2021

Type: PCT-Gov. Funding

Country of Filing: WO

Patent Number: (None)

Issue Date: (None)

Application Date: January 18, 2021

Type: NATL-Patent

Country of Filing: Canada

Patent Number: (None)

Issue Date: (None)

Application Date: January 18, 2021

Type: NATL-Patent

Country of Filing: Europe

Patent Number: (None)

Issue Date: (None)

Application Date: January 18, 2021

Type: NATL-Patent

Country of Filing: Japan
Patent Number: (None)
Issue Date: (None)

Application Date: March 18, 2020
Type: Provisional-Gov. Funding
Country of Filing: United States
Patent Number: (None)
Issue Date: (None)

Contact OTC:

Purdue Office of Technology Commercialization
The Convergence Center
101 Foundry Drive, Suite 2500
West Lafayette, IN 47906

Phone: (765) 588-3475
Fax: (765) 463-3486
Email: otcip@prf.org